GlassScriptPhysician profile
Hiba M Tamim
NPI 1114974888
$840.28
in general payments reported to CMS, 2019-2025
18 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $68.82 · 2021: $60.00 · 2022: $171 · 2023: $105 · 2024: $72.26 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.14 | 2019 | |
| Abbvie INC. | $124.78 | 2022-2024 | Venclexta |
| Astellas Pharma US INC | $109.93 | 2025 | Padcev, Xtandi |
| Puma Biotechnology, INC. | $106.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $59.56 | 2019-2023 | |
| Seagen INC. | $41.98 | 2020-2023 | Padcev |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.54 | 2019 | |
| Tersera Therapeutics LLC | $27.15 | 2024 | Zoladex |
| Genentech USA, INC. | $25.00 | 2022 | |
| Genzyme Corporation | $22.92 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2022 | |
| Amgen INC. | $18.87 | 2021 | |
| Eusa Pharma (US) LLC | $18.21 | 2021 | |
| Blueprint Medicines Corporation | $17.45 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.35 | 2020 | |
| Pfizer INC. | $14.03 | 2019 | |
| Foundation Medicine, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiba Tamim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.